$14.580
-1.126 (-7.72%)收盘时
IMUX 资讯
IMUX 事件
Immunic Appoints Chitrang Dave as Chief Data and Digital Officer
Immunic announced the appointment of Chitrang Dave as chief data and digital officer, effective immediately. Dave will report directly to CEO Erik Lundgren and will serve as a member of the executive leadership team. In this newly created C-suite role, Dave will establish and lead Immunic's enterprise-wide data systems, analytics, AI, and digital strategy, building a unified organization spanning data science, data engineering, data management, and digital capabilities to support the company's transition from late-stage clinical development to commercial readiness.
Immunic CEO Highlights Company Development Strategy and MS Expert Team
"During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic," said Erik Lundgren, Chief Executive Officer of Immunic. "As we prepare for the next stage of Immunic's growth, we have continued to strengthen our board and team with world-class multiple sclerosis (MS) experts whose extensive development, medical, regulatory and commercialization expertise will be instrumental as we execute on our clinical strategy and prepare for the potential regulatory filings and commercialization of vidofludimus calcium (IMU-838). Following the successful closing of our oversubscribed private placement financing earlier this year, we are well capitalized to execute on our key strategic priorities. We believe the milestones ahead position Immunic for a significant near-term value inflection for vidofludimus calcium in relapsing MS, while continuing to unlock the substantial long-term opportunity across the broader progressive MS patient population."
Immunic Appoints Erik Lundgren as CEO
Immunic announced the appointment of Erik Lundgren as CEO, effective May 22, with employment beginning on June 1. Lundgren succeeds Daniel Vitt, who will retain responsibility for scientific strategy and portfolio advancement while remaining a member of Immunic's board of directors. Lundgren will lead Immunic as the company advances vidofludimus calcium through late-stage clinical development, including the phase 3 ENSURE program in relapsing multiple sclerosis and the planned phase 3 program in primary progressive multiple sclerosis, while also preparing for potential new drug application filing, regulatory approval and commercialization. Lundgren spent more than a decade at Genentech in roles of increasing responsibility.
Immunic Appoints Michael Bonney as Board Chair
Immunic (IMUX) announced the appointment of Michael Bonney as chair of its board of directors, effective May 16. Simona Skerjanec will transition from interim chairperson to continue serving as a member of the board. During his tenure at Biogen (BIIB), he held senior commercial leadership roles.
Immunic Appoints New CMO to Support Key Clinical Trials
"We are fast approaching a highly pivotal juncture, with the anticipated top-line data readout of the twin phase 3 ENSURE trials of our lead asset, orally available nuclear receptor-related 1 activator, vidofludimus calcium, in relapsing multiple sclerosis, expected by the end of 2026," stated Daniel Vitt, CEO of Immunic. "In anticipation, we strengthened our leadership team with the recent appointment of Dr. Michael A. Panzara as Chief Medical Officer. Mike brings deep expertise in neurology and a proven track record of advancing multiple sclerosis therapies through late-stage clinical development and global regulatory approvals. Additionally, we enhanced our Board of Directors with the appointment of Jon Congleton, who has nearly four decades of biopharmaceutical leadership experience. Earlier in the quarter, Simona Skerjanec, M.Pharm, M.B.A., who joined Immunic's Board of Directors in July 2024, has been elevated to interim Chairperson of the Board and Thor Nagel, Principal at BVF Partners L.P., has been appointed as a member of the Board. Together, these key appointments are intended to best position the company for successful execution of our late-stage development priorities and prepare for potential commercialization."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。